Distinguish primary and secondary endpoints and give an example of each in a phase III oncology trial.

Prepare for the Drug Discovery and Healthcare Systems Test. Access flashcards and multiple-choice questions with hints and explanations. Ace your exam with our comprehensive resources!

Multiple Choice

Distinguish primary and secondary endpoints and give an example of each in a phase III oncology trial.

The main idea being tested is how primary and secondary endpoints differ in a phase III oncology trial. In this setting, the primary endpoint is the single main outcome used to judge whether the treatment works, while secondary endpoints provide additional information about other aspects of benefit and safety. Overall survival is often the primary endpoint in phase III cancer trials because it directly measures how long patients live, which is the most meaningful patient-centered outcome. Secondary endpoints, such as progression-free survival and objective response rate, add detail: progression-free survival tracks the time before the disease worsens or death, offering an earlier signal of activity, and objective response rate reflects how many patients experience tumor shrinkage. Together, they give a comprehensive view of benefit—survival as the primary measure, with activity and disease-control signals as supportive endpoints. Other endpoints like quality of life or toxicity are important but are typically reported as secondary, since they describe aspects of patient experience and safety rather than the primary measure of clinical benefit.

The main idea being tested is how primary and secondary endpoints differ in a phase III oncology trial. In this setting, the primary endpoint is the single main outcome used to judge whether the treatment works, while secondary endpoints provide additional information about other aspects of benefit and safety. Overall survival is often the primary endpoint in phase III cancer trials because it directly measures how long patients live, which is the most meaningful patient-centered outcome. Secondary endpoints, such as progression-free survival and objective response rate, add detail: progression-free survival tracks the time before the disease worsens or death, offering an earlier signal of activity, and objective response rate reflects how many patients experience tumor shrinkage. Together, they give a comprehensive view of benefit—survival as the primary measure, with activity and disease-control signals as supportive endpoints. Other endpoints like quality of life or toxicity are important but are typically reported as secondary, since they describe aspects of patient experience and safety rather than the primary measure of clinical benefit.

More practice questions